Search Results - "Hospers, Geke AP"

Quantitative fluorescence endoscopy: an innovative endoscopy approach to evaluate neoadjuvant treatment response in locally advanced rectal cancer by Tjalma, Jolien J J, Koller, Marjory, Linssen, Matthijs D, Hartmans, Elmire, de Jongh, Steven J, Jorritsma-Smit, Annelies, Karrenbeld, Arend, de Vries, Elisabeth G, Kleibeuker, Jan H, Pennings, Jan Pieter, Havenga, Klaas, Hemmer, Patrick Hjh, Hospers, Geke Ap, van Etten, Boudewijn, Ntziachristos, Vasilis, van Dam, Gooitzen M, Robinson, Dominic J, Nagengast, Wouter B

Get more information

Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial by Nilsson, Per J, van Etten, Boudewijn, Hospers, Geke A P, Påhlman, Lars, van de Velde, Cornelis J H, Beets-Tan, Regina G H, Blomqvist, Lennart, Beukema, Jannet C, Kapiteijn, Ellen, Marijnen, Corrie A M, Nagtegaal, Iris D, Wiggers, Theo, Glimelius, Bengt

“…Current standard for most of the locally advanced rectal cancers is preoperative chemoradiotherapy, and, variably per institution, postoperative adjuvant…”
Get full text

Relevance of shrinkage versus fragmented response patterns in rectal cancer by Kus Ozturk, Sonay, Graham Martinez, Cristina, Sheahan, Kieran, Winter, Desmond C, Aherne, Susan, Ryan, Éanna J, van de Velde, Cornelis JH, Marijnen, Corrie AM, Hospers, Geke AP, Roodvoets, Annet GH, Doukas, Michail, Mens, David, Verhoef, Cornelis, van der Post, Rachel S, Nagtegaal, Iris D

“…Aims Partial response to neoadjuvant chemoradiotherapy (CRT) presents with one of two main response patterns: shrinkage or fragmentation. This study…”
Get full text

A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report by Oosting, Sjoukje F, Peters, Frans Tm, Hospers, Geke Ap, Mulder, Nanno H

“…We report a rare case of gastrointestinal perforation following dacarbazine infusion for metastatic melanoma. The condition is attributed to a responding…”
Get full text

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study by van der Kooij, Monique K, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van Breeschoten, Jesper, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Wouters, Michel W J M, Dekkers, Olaf M, Kapiteijn, Ellen

“…Because immune checkpoint inhibition (ICI) can cause immune-related adverse events (irAEs) mimicking immunologic diseases, patients with preexisting autoimmune…”
Get full text

Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer by de Jongh, Steven J, Tjalma, Jolien J J, Koller, Marjory, Linssen, Matthijs D, Vonk, Jasper, Dobosz, Michael, Jorritsma-Smit, Annelies, Kleibeuker, Jan H, Hospers, Geke A P, Havenga, Klaas, Hemmer, Patrick H J, Karrenbeld, Arend, van Dam, Gooitzen M, van Etten, Boudewijn, Nagengast, Wouter B

“…Negative circumferential resection margins (CRM) are the cornerstone for the curative treatment of locally advanced rectal cancer (LARC). However, in up to…”
Get full text

Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice by van der Veen, Elly L, Suurs, Frans V, Cleeren, Frederik, Bormans, Guy, Elsinga, Philip H, Hospers, Geke A P, Lub-de Hooge, Marjolijn N, de Vries, Elisabeth G E, de Vries, Erik F J, Antunes, Inês F

“…Recently, -(4- F-fluorobenzoyl)-interleukin-2 ( F-FB-IL2) was introduced as a PET tracer for T cell imaging. However, production is complex and time-consuming…”
Get full text

Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition by Boers, Jorianne, Venema, Clasina M., de Vries, Erik F.J., Glaudemans, Andor W.J.M., Kwee, Thomas C., Schuuring, Ed, Martens, John W.M., Elias, Sjoerd G., Hospers, Geke A.P., Schröder, Carolina P.

“…Adding cyclin-dependent kinase (CDK) inhibitor to endocrine treatment improves outcome in œstrogen receptor (ER) positive metastatic breast cancer, but…”
Get full text

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma by Kelderman, Sander, Heemskerk, Bianca, van Tinteren, Harm, van den Brom, Rob R. H., Hospers, Geke A. P., van den Eertwegh, Alfonsus J. M., Kapiteijn, Ellen W., de Groot, Jan Willem B., Soetekouw, Patricia, Jansen, Rob L., Fiets, Edward, Furness, Andrew J. S., Renn, Alexandra, Krzystanek, Marcin, Szallasi, Zoltan, Lorigan, Paul, Gore, Martin E., Schumacher, Ton N. M., Haanen, John B. A. G., Larkin, James M. G., Blank, Christian U.

“…Introduction Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase…”
Get full text

Value of 18F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study by Boers, Jorianne, Loudini, Naila, Brunsch, Celina L, Koza, Sylvia A, de Vries, Erik FJ, Glaudemans, Andor WJM, Hospers, Geke AP, Schröder, Carolina P

“…Breast cancer (BC) is a heterogeneous disease in which estrogen receptor (ER) expression plays an important role in most tumors. A clinical dilemma may arise…”
Get full text

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: comparison of 3-year data from PRADO and OpACIN-neo by Reijers, Irene LM, Menzies, Alexander M, Lopez-Yurda, Marta, Versluis, Judith M, Rozeman, Elisa A, Saw, Robyn PM, van Houdt, Winan J, Kapiteijn, Ellen, van der Veldt, Astrid AM, Suijkerbuijk, Karijn PM, Eriksson, Hanna, Hospers, Geke AP, MC Klop, Willem, Acosta, Alejandro Torres, Grijpink-Ongering, Lindsay, Gonzalez, Maria, van der Wal, Anja, Al-Mamgani, Abrahim, Spillane, Andrew J, Scolyer, Richard A, van de Wiel, Bart A, van Akkooi, Alexander CJ, Long, Georgina V, Blank, Christian U

Get full text

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands by Jochems, Anouk, Schouwenburg, Maartje G, Leeneman, Brenda, Franken, Margreet G, van den Eertwegh, Alfons J.M, Haanen, John B.A.G, Gelderblom, Hans, Uyl-de Groot, Carin A, Aarts, Maureen J.B, van den Berkmortel, Franchette W.P.J, Blokx, Willeke A.M, Cardous-Ubbink, Mathilde C, Groenewegen, Gerard, de Groot, Jan Willem B, Hospers, Geke A.P, Kapiteijn, Ellen, Koornstra, Rutger H, Kruit, Wim H, Louwman, Marieke W, Piersma, Djura, van Rijn, Rozemarijn S, ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W.J.M, van der Hoeven, Jacobus J.M

“…Abstract Background In recent years, the treatment of metastatic melanoma has changed dramatically due to the development of immune checkpoint and…”
Get full text

Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer by Boers, Jorianne, Venema, Clasina M., de Vries, Erik F.J., Hospers, Geke A.P., Boersma, Hendrikus H., Rikhof, Bart, Dorbritz, Christine, Glaudemans, Andor W.J.M., Schröder, Carolina P.

“…The androgen receptor (AR) is a potential target in metastatic breast cancer (MBC), and 16β-[18F]-fluoro-5α-dihydrotestosterone positron emission tomography…”
Get full text

18F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study by Nienhuis, Pieter H, Antunes, Inês F, Glaudemans, Andor WJM, Jalving, Mathilde, Leung, David, Noordzij, Walter, Slart, Riemer HJA, de Vries, Erik FJ, Hospers, Geke AP

“…Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) frequently induces tumor response…”
Get full text

Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study by van Not, Olivier J., de Meza, Melissa M., van den Eertwegh, Alfons J.M., Haanen, John B., Blank, Christian U., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., van Breeschoten, Jesper, de Groot, Jan-Willem B., Hospers, Geke A.P., Ismail, Rawa K., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Stevense-den Boer, Marion A.M., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, Bonenkamp, Han J., Boers-Sonderen, Marye J., Blokx, Willeke A.M., Wouters, Michel W.J.M., Suijkerbuijk, Karijn P.M.

“…Recent reports suggest the limited efficacy of immune checkpoints inhibitors in advanced acral melanoma (AM). This study aims to investigate the clinical…”
Get full text

Abstract 803: Visualizing bicalutamide effect on androgen receptor availability in patients with metastatic breast cancer by Boers, Jorianne, Venema, Clasina M., de Vries, Erik FJ, Hospers, Geke AP, Boersma, Hendrikus H., Rikhof, Bart, Dorbritz, Christine, Glaudemans, Andor WJM, Schröder, Carolina P.

“…Abstract BACKGROUND: The androgen receptor (AR) is a potential new therapeutic target in metastatic breast cancer, but it is likely that only patients with…”
Get full text

PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma by van Kruchten, Michel, Glaudemans, Andor W J M, de Vries, Erik F J, Beets-Tan, Regina G H, Schröder, Carolien P, Dierckx, Rudi A, de Vries, Elisabeth G E, Hospers, Geke A P

“…16α-(18)F-fluoro-17β-estradiol ((18)F-FES) is an estrogen receptor (ER)-specific PET tracer with various potential interesting applications. The precise…”
Get full text

Comment on the RAPIDO Trial Point-Counterpoint Debate by Nilsson, Per J, van Etten, Boudewijn, Hospers, Geke A P, Marijnen, Corrie A M, Meershoek-Klein Kranenberg, Elma, Roodvoets, Annet G H, van de Velde, Cornelis J H, Glimelius, Bengt

Get full text

Adjuvant treatment for melanoma in clinical practice – Trial versus reality by de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., Wouters, Michel W.J.M.

“…Little is known about outcomes of adjuvant-treated melanoma patients beyond the clinical trial setting. Since 2019, adjuvant-treated melanoma patients have…”
Get full text

Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies by Venema, Clasina M, Mammatas, Lemonitsa H, Schröder, Carolina P, van Kruchten, Michel, Apollonio, Giulia, Glaudemans, Andor W J M, Bongaerts, Alfons H H, Hoekstra, Otto S, Verheul, Henk M W, Boven, Epi, van der Vegt, Bert, de Vries, Erik F J, de Vries, Elisabeth G E, Boellaard, Ronald, Menke van der Houven van Oordt, Catharina W, Hospers, Geke A P

“…In addition to the well-known estrogen receptor (ER) and human epidermal growth factor receptor 2, the androgen receptor (AR) is also a potential drug target…”
Get full text